04:23 AM EST, 11/25/2024 (MT Newswires) -- Edwards Lifesciences ( EW ) said Monday that an analysis of data from more than 9,000 patients showed that those who received the company's newest generation Sapien 3 Ultra Resilia heart valve experienced one-year outcomes that surpassed recipients of earlier generation Sapien 3 and Sapien 3 Ultra valves.

According to Edwards, patients with the valve showed "extremely low mortality, low rates of reintervention, larger effective orifice areas, lower echo-derived gradients across all valve sizes and no paravalvular leak in 84.4% of cases."